Table 2.
Changes in cellular immune indicators in the PMN patients before and after RTX treatment
| Before treatment (n = 40) | 6 months after RTX (n = 40) | T/Z | P | |
|---|---|---|---|---|
| CD3 + T, cells/µl | 1239.61(1051.61, 1549.25) | 1219.13(964.04, 1497.86) | -1.438 | 0.150 |
| CD3 + CD4 + T, cells/µl | 851.43(695.34, 1065.91) | 793.47(631.40, 977.24) | -1.317 | 0.188 |
| CD4 + central memory T, cells/µl | 234.40(16.10, 351.96) | 192.21(147.13, 284.50) | -1.317 | 0.188 |
| CD4 + effect memory T, cells/µl | 288.19(201.33, 391.48) | 301.06(232.56, 364.90) | -0.430 | 0.667 |
| CD4 + CD25 + T, cells/µl | 22.82(8.74, 44.30) | 12.07(2.90, 26.64) | -2.419 | 0.016 |
| CD4 + CD25 + CD127 lo T (Treg), cells/µl | 36.15(21.59, 55.58) | 46.46(31.44, 68.63) | -2.352 | 0.019 |
| CD3 + CD8 + T, cells/µl | 256.93(191.14, 335.21) | 283.47(202.70, 515.05) | -1.828 | 0.068 |
| CD8 + central memory T, cells/µl | 9.60(5.87, 15.92) | 11.52(5.55, 18.90) | -0.659 | 0.510 |
| CD8 + effect memory T, cells/µl | 93.59(76.32, 174.86) | 114.75(73.03, 91.00) | -0.301 | 0.763 |
| CD8 + CD25 + T, cells/µl | 0.87(0.08, 4.03) | 1.43(0.30, 7.44) | -2.050 | 0.040 |
| CD4 + /CD8 + | 3.20(2.36, 5.05) | 2.80(1.91, 3.60) | -3.051 | 0.002 |
| CD3 + CD4 - CD8 - T, cells/µl | 109.43(54.89, 165.58) | 12.27(4.59, 102.58) | -1.507 | 0.132 |
| CD16 + CD56 + NK, cells/µl | 243.41(201.33, 453.88) | 317.06(175.63, 490.22) | -1.129 | 0.259 |
| CD3 - CD19 + B, cells/µl | 268.30(179.58, 371.47) | 11.89(1.60, 102.39) | -5.256 | < 0.001 |
PMN, Primary membranous nephropathy; RTX, rituximab